Trial · NCT04598477
Adverse events84
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 84
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | INCREASED TENDENCY TO BRUISE | Blood and lymphatic system disorders | Efgartigimod-efgartigimod PH20 SC | 0 | 101 | |
| other | INCREASED TENDENCY TO BRUISE | Blood and lymphatic system disorders | Placebo-efgartigimod PH20 SC | 3 | 48 | |
| other | TACHYCARDIA | Cardiac disorders | Efgartigimod-efgartigimod PH20 SC | 1 | 101 | |
| other | TACHYCARDIA | Cardiac disorders | Placebo-efgartigimod PH20 SC | 3 | 48 | |
| other | INJECTION SITE ERYTHEMA | General disorders | Efgartigimod-efgartigimod PH20 SC | 4 | 101 | |
| other | INJECTION SITE ERYTHEMA | General disorders | Placebo-efgartigimod PH20 SC | 3 | 48 | |
| other | COVID-19 | Infections and infestations | Efgartigimod-efgartigimod PH20 SC | 12 | 101 | |
| other | COVID-19 | Infections and infestations | Placebo-efgartigimod PH20 SC | 5 | 48 | |
| other | FOLLICULITIS | Infections and infestations | Efgartigimod-efgartigimod PH20 SC | 5 | 101 | |
| other | FOLLICULITIS | Infections and infestations | Placebo-efgartigimod PH20 SC | 1 | 48 | |
| other | NASOPHARYNGITIS | Infections and infestations | Efgartigimod-efgartigimod PH20 SC | 5 | 101 | |
| other | NASOPHARYNGITIS | Infections and infestations | Placebo-efgartigimod PH20 SC | 1 | 48 | |
| other | ORAL CANDIDIASIS | Infections and infestations | Efgartigimod-efgartigimod PH20 SC | 6 | 101 | |
| other | ORAL CANDIDIASIS | Infections and infestations | Placebo-efgartigimod PH20 SC | 0 | 48 | |
| other | URINARY TRACT INFECTION | Infections and infestations | Efgartigimod-efgartigimod PH20 SC | 5 | 101 | |
| other | URINARY TRACT INFECTION | Infections and infestations | Placebo-efgartigimod PH20 SC | 2 | 48 | |
| other | BLOOD LACTATE DEHYDROGENASE INCREASED | Investigations | Efgartigimod-efgartigimod PH20 SC | 7 | 101 | |
| other | BLOOD LACTATE DEHYDROGENASE INCREASED | Investigations | Placebo-efgartigimod PH20 SC | 1 | 48 | |
| other | BLOOD URIC ACID INCREASED | Investigations | Efgartigimod-efgartigimod PH20 SC | 5 | 101 | |
| other | BLOOD URIC ACID INCREASED | Investigations | Placebo-efgartigimod PH20 SC | 0 | 48 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04598477/events